Compare Bristol-Myers Squibb Co (BMY) vs Hims and Hers Health Inc (HIMS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Hims and Hers Health Inc — how do they compare? Bristol-Myers Squibb Co trades at $56.99 (market cap $116.30B), while Hims and Hers Health Inc trades at $35.3 (market cap $8.14B). The key difference: Bristol-Myers Squibb Co is far larger — about 14.3× Hims and Hers Health Inc's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals.
| BMY | HIMS | |
|---|---|---|
Market Cap | $116.30B | $8.14B |
Sector | Health | Health |
52-Week High | $62.37 | $66.18 |
52-Week Low | $42.60 | $14.52 |
Enterprise Value | $152.24B | $8.52B |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Hims & Hers Health trades at $34.38, showing no change in the last session. The stock exhibits a bullish technical setup with moving averages supporting upward momentum, while oscillators remain neutral. Recent earnings have been mixed, with Q1 2026 missing expectations, but revenue growth remains positive. Analyst sentiment is divided with a 35% buy rating, and the consensus price target is $33.57. News highlights include expansion in weight-loss treatments and a new JPMorgan receivables facility.
The outlook for HIMS is cautiously optimistic, driven by growth in telehealth and weight-loss segments, but high valuation multiples and recent net income declines pose risks. Investment opportunity lies in market expansion and subscriber growth, while execution risks and competitive pressures require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →
